Effects of combinations of a prostacyclin analogue (Cicaprost) with different antithrombotic agents in a rat microcirculatory thrombosis model.
The antithrombotic effects of the stable PGI2-analogue Cicaprost, acetylsalicylic acid (Aspisol), the low molecular weight heparin CY 216 (Fraxiparin) and Molsidomin (Corvaton) have been investigated alone and in combinations in a thrombosis model in rats in which mesenteric venules with a diameter of 20-30 microns were injured by defined argon laser lesions. In this animal thrombosis model all agents showed a significant and dose-dependent antithrombotic effect. A strong additive effect was observed when Cicaprost was infused together with an i.v. dose of 0.1 mg/kg Molsidomin. A similar additive effect was observed after infusion of minimal effective doses of Cicaprost together with Fraxiparin. The combination of Cicaprost and Aspisol did not have any additive effect. Our results suggest that combinations of antithrombotic agents which show additive effects in animal thrombosis model may lead to a more effective prophylaxis and treatment of human venous or arterial thrombosis.
Giedrojc
J
J
Department of Angiology, University of Frankfurt/Main, Germany.
Breddin
H K
HK
D000818:Animals; D001241:Aspirin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008981:Molsidomine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D013927:Thrombosis / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D008981:Molsidomine; D011464:Epoprostenol; D008239:Lysine; C043867:cicaprost; D001241:Aspirin; C010395:acetylsalicylic acid lysinate